Alcon, the eye-care division of Novartis, has agreed to acquire Transcend Medical, Inc., a privately held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma.

Transcend Medical, has recently developed a micro-stent to treat mild to moderate glaucoma. The MIGS device is implanted just below the surface of the eye. It is designed to treat less severe glaucoma by enhancing part of the natural drainage pathways of the eye with minimal tissue disruption. This allows the excess fluid in the eye to drain with the goal of reducing intraocular pressure (IOP) levels.m

Source: Novartis